112 related articles for article (PubMed ID: 10073373)
1. Cost-utility analysis in schizophrenia.
Awad AG; Voruganti LP
J Clin Psychiatry; 1999; 60 Suppl 3():22-6; discussion 27-8. PubMed ID: 10073373
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
[TBL] [Abstract][Full Text] [Related]
5. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
Revicki DA
J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
[TBL] [Abstract][Full Text] [Related]
6. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W; Schimmelmann BG; Lambert M
J Psychiatr Res; 2008 Jul; 42(8):676-83. PubMed ID: 17720192
[TBL] [Abstract][Full Text] [Related]
7. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
10. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
Meltzer D
J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics in the managed care era.
Loebel AD; Botts SR; Feldman BI
Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
[TBL] [Abstract][Full Text] [Related]
12. Limitations of current therapies: why do patients switch therapies?
Falkai P
Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S135-9. PubMed ID: 18502616
[TBL] [Abstract][Full Text] [Related]
13. The cost of schizophrenia.
Wasylenki DA
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S65-9. PubMed ID: 7874667
[TBL] [Abstract][Full Text] [Related]
14. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice.
Mahmoud R; Engelhart L; Ollendorf D; Oster G
J Clin Psychiatry; 1999; 60 Suppl 3():42-7; discussion 48. PubMed ID: 10073377
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomics of schizophrenia in the 21st century.
Hanson MA
J Clin Psychiatry; 1999; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
[TBL] [Abstract][Full Text] [Related]
18. Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study.
Puschner B; Born A; Giessler A; Helm H; Leese M; Bindman JP; Gray RJ; Schene A; Kikkert M; Burti L; Marrella G; Becker T
J Nerv Ment Dis; 2006 Oct; 194(10):746-52. PubMed ID: 17041286
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
20. Quality of life measurement during antipsychotic drug therapy of schizophrenia.
Voruganti LN; Heslegrave RJ; Awad AG
J Psychiatry Neurosci; 1997 Jul; 22(4):267-74. PubMed ID: 9262049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
